Consano Bio
June 17, 2025
Company Presentation
Regenerative Medicine
Consano Bio is developing a first in category, disease modifying Biologic to treat radicular pain. We have submitted our first IND (CBER) for the treatment of chronic Lumbosacral Radiculopathy, a disease for which there is no FDA approved therapy.
We have demonstrated preclinical evidence for reparative anti-inflammatory and growth factor activity that drives cellular healing and repair and in a model of neuropathic pain, we have shown significant recovery of nerve function.
We have developed scalable manufacturing, generated three families of Intellectual Protection and will dose our first patient in a phase I study in Q3 2025
Company HQ City:
Burlington
Company HQ State:
MA
Company HQ Country:
United States
Year Founded:
2024
Lead Product in Development:
C-1101
CEO
Andrew Hall
Development Phase of Lead Product
Phase I
Number of Unlicensed Products Looking for Licensing
0
When you expect your next catalyst update?
IND acceptance and phase I start
What is your next catalyst (value inflection) update?
Q3 2025
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}